Conditions: Carcinoma, Renal Cell
Keywords: Ph2, RCC, SU011248, SUNITINIB
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 51
Healthy volunteers: no

Brief summary:
To determine the objective tumor response of single-agent SU011248 at a dose of 50 mg orally once daily for 4 consecutive weeks and 2 weeks rest, repeated every 6 weeks in patients with metastatic Renal Cell Cancer (RCC).

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: SU011248 capsule
Intervention descriptions: intervention 1: 50mg, PO on day 28 of each 42 day cycle, until progression or unacceptable toxicity develops

Protocol document: